MA48936A - Formulation à base de vitamine e ou d'un ester de celle-ci pour traiter les biofilms bactériens et fongiques - Google Patents

Formulation à base de vitamine e ou d'un ester de celle-ci pour traiter les biofilms bactériens et fongiques

Info

Publication number
MA48936A
MA48936A MA048936A MA48936A MA48936A MA 48936 A MA48936 A MA 48936A MA 048936 A MA048936 A MA 048936A MA 48936 A MA48936 A MA 48936A MA 48936 A MA48936 A MA 48936A
Authority
MA
Morocco
Prior art keywords
vitamin
ester
treating bacterial
formulation based
fungal biofilms
Prior art date
Application number
MA048936A
Other languages
English (en)
Other versions
MA48936B1 (fr
Inventor
Giorgio Panin
Original Assignee
Bio Lo Ga Srl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bio Lo Ga Srl filed Critical Bio Lo Ga Srl
Publication of MA48936A publication Critical patent/MA48936A/fr
Publication of MA48936B1 publication Critical patent/MA48936B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Food Preservation Except Freezing, Refrigeration, And Drying (AREA)
  • Medicinal Preparation (AREA)
MA48936A 2017-05-29 2018-05-28 Formulation à base de vitamine e ou d'un ester de celle-ci pour traiter les biofilms bactériens et fongiques MA48936B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT102017000058311A IT201700058311A1 (it) 2017-05-29 2017-05-29 Formulazione a base di vitamina E o di un suo estere per il trattamento di biofilm batterici e fungini
PCT/EP2018/063926 WO2018219862A1 (fr) 2017-05-29 2018-05-28 Formulation à base de vitamine e ou d'un ester de celle-ci pour traiter les biofilms bactériens et fongiques

Publications (2)

Publication Number Publication Date
MA48936A true MA48936A (fr) 2020-04-08
MA48936B1 MA48936B1 (fr) 2022-08-31

Family

ID=60294053

Family Applications (1)

Application Number Title Priority Date Filing Date
MA48936A MA48936B1 (fr) 2017-05-29 2018-05-28 Formulation à base de vitamine e ou d'un ester de celle-ci pour traiter les biofilms bactériens et fongiques

Country Status (22)

Country Link
US (3) US20200360339A1 (fr)
EP (1) EP3630092B1 (fr)
CN (1) CN110650737A (fr)
AU (1) AU2018275487B2 (fr)
BR (1) BR112019023962A8 (fr)
CA (1) CA3061568C (fr)
CL (1) CL2019003254A1 (fr)
DK (1) DK3630092T3 (fr)
EA (1) EA201992190A1 (fr)
ES (1) ES2919423T3 (fr)
GE (1) GEP20207179B (fr)
HR (1) HRP20220808T1 (fr)
HU (1) HUE059185T2 (fr)
IT (1) IT201700058311A1 (fr)
LT (1) LT3630092T (fr)
MA (1) MA48936B1 (fr)
MX (1) MX2019013559A (fr)
PL (1) PL3630092T3 (fr)
PT (1) PT3630092T (fr)
RS (1) RS63347B1 (fr)
SI (1) SI3630092T1 (fr)
WO (1) WO2018219862A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT201700058311A1 (it) * 2017-05-29 2018-11-29 Bio Lo Ga Srl Formulazione a base di vitamina E o di un suo estere per il trattamento di biofilm batterici e fungini

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3755558A (en) * 1971-02-23 1973-08-28 Du Pont Polylactide drug mixtures for topical application atelet aggregation
JPH09169643A (ja) * 1995-12-22 1997-06-30 Sekisui Chem Co Ltd 寄生性皮膚疾患治療用外用剤
IT1302275B1 (it) * 1998-09-25 2000-09-05 Giorgio Panin Formulazione di gel idrofobo a base di vitamina e acetato perapplicazione topica.
ES2713349T3 (es) * 2009-04-15 2019-05-21 Bmg Pharma S P A Composiciones de sal mineral-ácido sulfónico y procedimientos de uso
ITUB20153889A1 (it) * 2015-09-25 2017-03-25 Bio Lo Ga Srl Gel idrofobico a base di vitamina E esente da prodotti siliconici per applicazione topica
ITUB20169882A1 (it) * 2016-01-08 2017-07-08 Flame S R L Vitamina E per l’uso nel trattamento e nella prevenzione delle infezioni da biofilm.
IT201700058311A1 (it) * 2017-05-29 2018-11-29 Bio Lo Ga Srl Formulazione a base di vitamina E o di un suo estere per il trattamento di biofilm batterici e fungini

Also Published As

Publication number Publication date
MA48936B1 (fr) 2022-08-31
ES2919423T3 (es) 2022-07-26
IT201700058311A1 (it) 2018-11-29
EP3630092B1 (fr) 2022-04-13
MX2019013559A (es) 2022-02-03
WO2018219862A1 (fr) 2018-12-06
CN110650737A (zh) 2020-01-03
GEAP201815201A (fr) 2020-07-27
US11234958B2 (en) 2022-02-01
CA3061568C (fr) 2024-02-13
US20200360339A1 (en) 2020-11-19
BR112019023962A8 (pt) 2022-07-05
BR112019023962A2 (pt) 2020-06-09
AU2018275487A1 (en) 2019-11-07
LT3630092T (lt) 2022-06-27
GEP20207179B (en) 2020-11-10
CL2019003254A1 (es) 2020-07-03
CA3061568A1 (fr) 2018-12-06
US20210228541A1 (en) 2021-07-29
SI3630092T1 (sl) 2022-08-31
PL3630092T3 (pl) 2022-09-12
DK3630092T3 (da) 2022-06-20
HUE059185T2 (hu) 2022-10-28
EA201992190A1 (ru) 2020-09-03
HRP20220808T1 (hr) 2022-09-30
US20200121638A1 (en) 2020-04-23
EP3630092A1 (fr) 2020-04-08
AU2018275487B2 (en) 2024-03-14
PT3630092T (pt) 2022-06-02
RS63347B1 (sr) 2022-07-29

Similar Documents

Publication Publication Date Title
MA49903A (fr) Sulfonylureés et sulfonylthioureés en tant qu'inhibiteurs de nlrp3
MA46466A (fr) Formulations pharmaceutiques de protéines à viscosité réduite
MA49043A (fr) Formulation stable d'anticorps
MA45688A (fr) Compositions et procédés de potentialisation d'agents antimicrobiens
MA56006A (fr) Formulations sous-cutanées d'anticorps her2
MA47310A (fr) Combinaisons de cabozantinib et d'atzolizumab pour traiter le cancer
MA50456A (fr) Formulations d'un inhibiteur de kinase trk macrocyclique
MA51616A (fr) Inhibiteurs d'adn-pk
MA46109A (fr) Formulations d'anticorps inhibiteurs de masp-2 hautement concentrées à faible viscosité, kits et méthodes
MA51747A (fr) Formulation d'anticorps pharmaceutique à ph faible
MA54052A (fr) Formulation d'anticorps
MA46685A (fr) Extrait d'une composition à base de plantes médicinales en tant qu'agent antimicrobien et/ou antibiofilm
MA54448A (fr) Dérivés naphthyridine et quinoléine en tant qu'inhibiteurs de alk5
MA49576A (fr) Compositions et méthodes pour le traitement d'infections fongiques
MA45226A (fr) Compositions et méthodes de traitement ou de prévention d'affections liées à l'oxalate
MA53924A (fr) Modulateurs de l'expression d'apol1
MA43825A (fr) Schémas posologiques pour le traitement d'infections fongiques
MA55033A (fr) Formulation d'anticorps thérapeutique
MA49259A (fr) Anticorps thérapeutiques à base d'hexamères d'igg mutées
MA44286A (fr) Formulation pharmaceutique de cinéol et d'amoxicilline
MA45794A (fr) Système de marqueur pour confirmer l'exactitude de compositions et de formulations agrochimiques
MA52306A (fr) Agents préventifs et thérapeutiques de la sarcopénie
MA48936A (fr) Formulation à base de vitamine e ou d'un ester de celle-ci pour traiter les biofilms bactériens et fongiques
MA49618A (fr) Inhibiteurs de la mpo destinés à être utilisés en médecine
MA52691A (fr) Compositions à base de statine et procédés destinés à être utilisés dans le traitement de synucléinopathies